跳至主要内容
临床试验/EUCTR2010-019296-30-GB
EUCTR2010-019296-30-GB进行中(未招募)不适用

A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degree relatives. - ALS deficiency: insulin resistance, bone strength & response to rhIGF1

niversity Hospital Birmingham NHS Foundation Trust0 个研究点开始时间: 2010年4月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • PK/PD study arm: Patients with confirmed IGFALS gene mutations, able to give informed consent
  • Cross-sectional study arm: Heterozygous first-degree relatives, able to give informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • PK/PD study arm: Patients currently receiving IncrelexTM treatment, patients allergic to Increlex, patients with cancer
  • Cross-sectional study arm: Individuals suffering from cancer or chronic inflammatory conditions (e.g. chronic rheumatoid arthritis, inflammatory bowels disease).

研究者

发起方
niversity Hospital Birmingham NHS Foundation Trust

相似试验